AtaiBeckley, formed through the strategic combination of atai Life Sciences and Beckley Psytech completed last year, is entering 2026 with significant momentum in developing treatments for difficult-to-treat mental health conditions. The company recently redomiciled to the United States from the Netherlands and reported financial resources to support operations into 2029.
The company is advancing three primary drug candidates through Phase 2 clinical development. BPL-003, a mebufotenin benzoate nasal spray for treatment-resistant depression and alcohol use disorder, demonstrated positive results in July 2025 from its Phase 2b dose-finding trial. Both 8 mg and 12 mg doses showed statistically significant and clinically meaningful reductions in depressive symptoms compared to a low-dose active control at all study time points through Week 8. In November 2025, the open-label extension study showed that a 12 mg dose administered eight weeks after an initial dose was well-tolerated and produced additional clinically meaningful antidepressant effects sustained for up to two months. The company anticipates guidance on the Phase 3 program in Q1’26 with trial initiation in Q2’26 pending an FDA End-of-Phase 2 meeting.
VLS-01, a dimethyltryptamine buccal film for treatment-resistant depression, is expected to deliver topline data from its Phase 2 trial in H2’26. EMP-01, an oral R-enantiomer of MDMA for social anxiety disorder, received a new patent from the United States Patent and Trademark Office in December 2025, expected to provide exclusivity through 2043. The company expects topline data from an exploratory Phase 2a study in Q1’26.
AtaiBeckley also announced its common stock had been added to the NASDAQ biotechnology index in December 2025. The redomiciliation completed in December creates alignment with its U.S. listing and shareholder base and is expected to reduce administrative burdens and costs.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://menafn.com/1110572599/Ataibeckley-Provides-Update-And-Outlook-For-2026-Ahead-Of-JP-Morgan-Healthcare-Conference